Video

Dr Peter P. Yu Talks About the Importance of Patient-Centered Oncology Care

The American Journal of Managed Care's Patient-Centered Oncology Care meeting is an important event for anyone interested in "crossing the chasm" that appears between providers and the rest of the healthcare world, explained Peter P. Yu, MD, president of the American Society of Clinical Oncology.

The American Journal of Managed Care's Patient-Centered Oncology Care meeting is an important event for anyone interested in "crossing the chasm" that appears between providers and the rest of the healthcare world, including payers and hospital administrators, explained Peter P. Yu, MD, president of the American Society of Clinical Oncology, and the keynote speaker from Patient-Centered Oncology Care 2014.

Related Videos
Dawn Klemow, MD, assistant clinical professor, The University of Texas Southwestern Medical Center
Jonathan Eisengart
Tiago Biachi, MD, PhD
Irina Dralyuk
Edgardo S. Santos, MD, FACP, FASCO
Irina Dralyuk
Keith Ferdinand, MD, professor of medicine and the Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine
Robin Glasco, Spencer Stuart
Edgardo S. Santos, MD, FACP, FASCO
Tiago Biachi, MD, PhD
Related Content
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Managed Care Cast
January 14th 2025

Frameworks for Advancing Health Equity: Accessing Ketamine-Assisted Therapy

Giuliana Grossi
Jessica Tracy, head of Growth and Partnerships at Enthea, shares how employers and unions can support mental health and address access barriers to evidence-based ketamine treatments.
Karen Winkfield, MD, PhD, Vanderbilt University Medical Center
January 15th 2025

Building Trust Through Community Engagement in Cancer Care

Maggie L. Shaw
In part 2 of our interview with Karen Winkfield, MD, PhD, she speaks to the importance of ensuring health care accessibility and of knowing that the health care system is not a one-size-fits-all arrangement.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024

Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Intrathecal onasemnogene abeparvovec is an investigational SMA gene therapy that has been evaluated in the phase 1/2 STRONG study, the phase 3B STRENGTH study, and the STEER study. | Image credit: wladimir1804 - stock.adobe.com
January 15th 2025

Phase 3 STEER Study of SMA Gene Therapy Meets Primary End Point

Rose McNulty
Patients with spinal muscular atrophy (SMA) type 2 showed improved motor ability when treated with intrathecal onasemnogene abeparvovec, an investigational gene therapy.
Marie-France Jilderda, MD, PhD Candidate Surgical Oncology at Leiden University Medical Center in the Netherlands.
January 15th 2025

BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer

Cameron Santoro
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo